It is no doubt that Pharma sector can grow at phenomenal rate in India as these companies manufacturing costs in India is nearly 40% lower when compared on the world platform. Moreover India has an advantage in that it has 107 plants approved by the US FDA, the highest number outside the US, and thrice the number in China.

However remember that Ranbaxy, Lupin and Sun Pharma have come under the USFDA scanner with Ranbaxy doing the worst among the three. However all is not lost as as US$ 100 bn worth of drugs will be going off patent in the next five years and thus great opportunity lies ahead for Indian firms.
Click here to Get Free Indian Stock Tips